Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propionibacterium freudenreichii is a species of Gram-positive bacterium traditionally used as a starter culture in the production of Swiss-type cheeses like Emmental, where its fermentation of lactic acid into propionic acid, acetic acid, and carbon dioxide creates the characteristic nutty flavor and "eyes" (holes). [2, 7, 18] Beyond its role in food production, it is recognized as a probiotic and is being investigated as a live biotherapeutic product. [6, 15] This bacterium is noted for its ability to survive the harsh conditions of the gastrointestinal tract. [9, 15] Its proposed mechanisms of action include modulating the gut microbiota, producing beneficial metabolites such as short-chain fatty acids (SCFAs) and vitamin B12, and exerting anti-inflammatory and immunomodulatory effects. [5, 6, 9] The production of SCFAs like propionate and acetate is linked to its ability to induce apoptosis in colon cancer cells. [2, 12, 13] Due to these properties, P. freudenreichii is under investigation for various therapeutic applications, including inflammatory bowel disease, colorectal cancer prevention, muscle atrophy, and managing symptoms of autism spectrum disorder. [2, 6, 8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propionibacterium freudenreichii.